Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis

Blood Cells, Molecules, and Diseases

Volumn 54, Issue 3, 2015, Pages 234-241

  Ciaffoni, Fiorella ^a   Cassella, Elena ^b   Varricchio, Lilian ^b   Massa, Margherita ^c   Barosi, Giovanni ^c,d   Migliaccio, Anna Rita ^b,d,e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Myeloproliferative Disorder Research Consortium   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autoimmunity; Inflammation; Myelofibrosis; TGF 1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; MITOCHONDRIAL DNA; MITOCHONDRION ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; AUTOIMMUNITY; BONE MARROW; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA REPAIR; DOWN REGULATION; EVI1 GENE; GENE; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEGAKARYOCYTE; MYELOID METAPLASIA; OSTEOBLAST; P21CIP1 GENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN; UPREGULATION; ANIMAL; FEMALE; IMMUNOLOGY; INFLAMMATION; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ERINACEIDAE;

ADULT; ANIMALS; AUTOIMMUNITY; BONE MARROW; FEMALE; HUMANS; INFLAMMATION; MALE; MEGAKARYOCYTES; MICE; PRIMARY MYELOFIBROSIS; SIGNAL TRANSDUCTION; SPLEEN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84923838840     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.12.005     Document Type: Article

References (43)

1. Ghosh A.K., Quaggin S.E., Vaughan D.E. Molecular basis of organ fibrosis: potential therapeutic approaches. Exp. Biol. Med. (Maywood) 2013, 238:461-481.
2. Massague J., Blain S.W., Lo R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
3. Kinoshita K., Iimuro Y., Otogawa K., Saika S., Inagaki Y., Nakajima Y., Kawada N., Fujimoto J., Friedman S.L., Ikeda K. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 2007, 56:706-714.
4. Fukasawa H., Yamamoto T., Togawa A., Ohashi N., Fujigaki Y., Oda T., Uchida C., Kitagawa K., Hattori T., Suzuki S., Kitagawa M., Hishida A. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8687-8692.
5. Liu G.X., Li Y.Q., Huang X.R., Wei L., Chen H.Y., Shi Y.J., Heuchel R.L., Lan H.Y. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-beta/Smad3-NF.kappaB-dependent mechanisms in mice. PLoS One 2013, 8:e53573.
6. Jin Y., Ratnam K., Chuang P.Y., Fan Y., Zhong Y., Dai Y., Mazloom A.R., Chen E.Y., D'Agati V., Xiong H., Ross M.J., Chen N., Ma'ayan A., He J.C. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat. Med. 2012, 18:580-588.
7. Gerber E.E., Gallo E.M., Fontana S.C., Davis E.C., Wigley F.M., Huso D.L., Dietz H.C. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013, 503:126-130.
8. Akhmetshina A., Palumbo K., Dees C., Bergmann C., Venalis P., Zerr P., Horn A., Kireva T., Beyer C., Zwerina J., Schneider H., Sadowski A., Riener M.O., MacDougald O.A., Distler O., Schett G., Distler J.H. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat. Commun. 2012, 3:735.
9. Tefferi A. Myelofibrosis with myeloid metaplasia. N. Engl. J. Med. 2000, 342:1255-1265.
10. Schmitt A., Jouault H., Guichard J., Wendling F., Drouin A., Cramer E.M. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000, 96:1342-1347.
11. Fleischman A.G., Aichberger K.J., Luty S.B., Bumm T.G., Petersen C.L., Doratotaj S., Vasudevan K.B., LaTocha D.H., Yang F., Press R.D., Loriaux M.M., Pahl H.L., Silver R.T., Agarwal A., O'Hare T., Druker B.J., Bagby G.C., Deininger M.W. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011, 118:6392-6398.
12. Campanelli R., Rosti V., Villani L., Castagno M., Moretti E., Bonetti E., Bergamaschi G., Balduini A., Barosi G., Massa M. Evaluation of the bioactive and total transforming growth factor beta1 levels in primary myelofibrosis. Cytokine 2011, 53:100-106.
13. low mouse model of myelofibrosis. Blood 2013, 121:3345-3363.
14. Chagraoui H., Komura E., Tulliez M., Giraudier S., Vainchenker W., Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100:3495-3503.
15. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., Barosi G., Verstovsek S., Birgegard G., Mesa R., Reilly J.T., Gisslinger H., Vannucchi A.M., Cervantes F., Finazzi G., Hoffman R., Gilliland D.G., Bloomfield C.D., Vardiman J.W. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
16. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., Van Dyke D., Hanson C., Wu W., Pardanani A., Cervantes F., Passamonti F., Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 2011, 29:392-397.
17. Tanaka A., Miyakawa H., Luketic V.A., Kaplan M., Storch W.B., Gershwin M.E. The diagnostic value of anti-mitochondrial antibodies, especially in primary biliary cirrhosis. Cell. Mol. Biol. (Noisy-le-Grand) 2002, 48:295-299.
18. Grassegger A., Pohla-Gubo G., Frauscher M., Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien. Med. Wochenschr. 2008, 158:19-28.
19. Gu Y., Filippi M.D., Cancelas J.A., Siefring J.E., Williams E.P., Jasti A.C., Harris C.E., Lee A.W., Prabhakar R., Atkinson S.J., Kwiatkowski D.J., Williams D.A. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003, 302:445-449.
20. low myelofibrosis mouse model by Aplidin. J. Cell. Physiol. 2010, 225:490-499.
21. Khandros E., Thom C.S., D'Souza J., Weiss M.J. Integrated protein quality-control pathways regulate free alpha-globin in murine beta-thalassemia. Blood 2012, 119:5265-5275.
22. Buonamici S., Li D., Chi Y., Zhao R., Wang X., Brace L., Ni H., Saunthararajah Y., Nucifora G. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 2004, 114:713-719.
23. Kreider B.L., Orkin S.H., Ihle J.N. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6454-6458.
24. Paulson R.F., Shi L., Wu D.C. Stress erythropoiesis: new signals and new stress progenitor cells. Curr. Opin. Hematol. 2011, 18:139-145.
25. Desterke C., Bilhou-Nabera C., Guerton B., Martinaud C., Tonetti C., Clay D., Guglielmelli P., Vannucchi A., Bordessoule D., Hasselbalch H., Dupriez B., Benzoubir N., Bourgeade M.F., Pierre-Louis O., Lazar V., Vainchenker W., Bennaceur-Griscelli A., Gisslinger H., Giraudier S., Le Bousse-Kerdiles M.C. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res. 2011, 71:2901-2915.
26. Wang X., Prakash S., Lu M., Tripodi J., Ye F., Najfeld V., Li Y., Schwartz M., Weinberg R., Roda P., Orazi A., Hoffman R. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J. Clin. Invest. 2012, 122:3888-3899.
27. Vallier L., Alexander M., Pedersen R.A. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J. Cell Sci. 2005, 118:4495-4509.
28. Zhang Y.Q., Sterling L., Stotland A., Hua H., Kritzik M., Sarvetnick N. Nodal and lefty signaling regulates the growth of pancreatic cells. Dev. Dyn. 2008, 237:1255-1267.
29. Hattangadi S.M., Burke K.A., Lodish H.F. Homeodomain-interacting protein kinase 2 plays an important role in normal terminal erythroid differentiation. Blood 2010, 115:4853-4861.
30. Yang M., Li K., Ng M.H., Yuen P.M., Fok T.F., Li C.K., Hogg P.J., Chong B.H. Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36. Thromb. Res. 2003, 109:47-54.
31. Liebermann D.A., Tront J.S., Sha X., Mukherjee K., Mohamed-Hadley A., Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit. Rev. Oncog. 2011, 16:129-140.
32. O'Malley D.P., Orazi A., Wang M., Cheng L. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Mod. Pathol. 2005, 18:1562-1568.
33. Saffarzadeh M., Preissner K.T. Fighting against the dark side of neutrophil extracellular traps in disease: manoeuvres for host protection. Curr. Opin. Hematol. 2013, 20:3-9.
34. low mice. Blood 2004, 104:3573-3580.
35. Thiele J., Lorenzen J., Manich B., Kvasnicka H.M., Zirbes T.K., Fischer R. Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. Acta Haematol. 1997, 97:137-143.
36. Barosi G., Magrini U., Gale R.P. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?. Leuk. Res. 2010, 34:1119-1120.
37. Barcellini W., Iurlo A., Radice T., Imperiali F.G., Zaninoni A., Fattizzo B., Guidotti F., Bianchi P., Fermo E., Consonni D., Cortelezzi A. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk. Res. 2013, 37:1509-1515.
38. Kristinsson S.Y., Landgren O., Samuelsson J., Bjorkholm M., Goldin L.R. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010, 95:1216-1220.
39. Mascarenhas J., Li T., Sandy L., Newsom C., Petersen B., Godbold J., Hoffman R. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk. Lymphoma 2014, 55:450-452.
40. Lu M., Zhang W., Li Y., Berenzon D., Wang X., Wang J., Mascarenhas J., Xu M., Hoffman R. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp. Hematol. 2010, 38:472-480.
41. Katsoulidis E., Li Y., Yoon P., Sassano A., Altman J., Kannan-Thulasiraman P., Balasubramanian L., Parmar S., Varga J., Tallman M.S., Verma A., Platanias L.C. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res. 2005, 65:9029-9037.
42. Zawistowski J.S., Nakamura K., Parker J.S., Granger D.A., Golitz B.T., Johnson G.L. MicroRNA 9-3p targets beta1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Mol. Cell. Biol. 2013, 33:2260-2274.
43. Chang-Yew Leow C., Gerondakis S., Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J. 2013, 3:e105.